Frank Rimerman Advisors LLC Acquires 2,451 Shares of Moderna, Inc. (NASDAQ:MRNA)

Frank Rimerman Advisors LLC lifted its holdings in shares of Moderna, Inc. (NASDAQ:MRNA) by 349.6% in the 2nd quarter, HoldingsChannel.com reports. The fund owned 3,152 shares of the company’s stock after purchasing an additional 2,451 shares during the quarter. Frank Rimerman Advisors LLC’s holdings in Moderna were worth $374,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also made changes to their positions in the company. Profund Advisors LLC lifted its holdings in Moderna by 20.9% during the 2nd quarter. Profund Advisors LLC now owns 56,218 shares of the company’s stock valued at $6,676,000 after purchasing an additional 9,719 shares during the last quarter. Summit Trail Advisors LLC lifted its stake in shares of Moderna by 12.8% during the 2nd quarter. Summit Trail Advisors LLC now owns 3,558 shares of the company’s stock worth $423,000 after buying an additional 403 shares during the last quarter. Pacer Advisors Inc. boosted its holdings in shares of Moderna by 9.5% during the 2nd quarter. Pacer Advisors Inc. now owns 45,298 shares of the company’s stock worth $5,379,000 after buying an additional 3,930 shares during the period. Skandinaviska Enskilda Banken AB publ grew its stake in Moderna by 0.3% in the 2nd quarter. Skandinaviska Enskilda Banken AB publ now owns 245,687 shares of the company’s stock valued at $29,150,000 after buying an additional 706 shares during the last quarter. Finally, Benjamin F. Edwards & Company Inc. raised its holdings in Moderna by 297.2% in the 2nd quarter. Benjamin F. Edwards & Company Inc. now owns 5,343 shares of the company’s stock valued at $634,000 after acquiring an additional 3,998 shares during the period. 75.33% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

MRNA has been the subject of a number of research analyst reports. JPMorgan Chase & Co. cut Moderna from a “neutral” rating to an “underweight” rating and reduced their price objective for the stock from $88.00 to $70.00 in a report on Friday, September 13th. Bank of America decreased their price objective on Moderna from $130.00 to $110.00 and set a “neutral” rating on the stock in a report on Friday, September 13th. Piper Sandler dropped their target price on Moderna from $157.00 to $115.00 and set an “overweight” rating for the company in a report on Friday, September 13th. Royal Bank of Canada restated a “sector perform” rating and issued a $75.00 price target on shares of Moderna in a research note on Thursday, September 19th. Finally, HSBC upgraded shares of Moderna from a “reduce” rating to a “hold” rating and set a $82.00 price objective for the company in a research note on Wednesday, August 28th. Two analysts have rated the stock with a sell rating, thirteen have given a hold rating and four have assigned a buy rating to the company’s stock. According to data from MarketBeat, Moderna presently has an average rating of “Hold” and an average target price of $100.44.

Insider Transactions at Moderna

In related news, Director Noubar Afeyan sold 15,000 shares of Moderna stock in a transaction that occurred on Wednesday, July 17th. The shares were sold at an average price of $122.84, for a total transaction of $1,842,600.00. Following the sale, the director now directly owns 2,254,015 shares of the company’s stock, valued at approximately $276,883,202.60. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In other news, Director Noubar Afeyan sold 15,000 shares of the stock in a transaction on Wednesday, July 17th. The stock was sold at an average price of $122.84, for a total value of $1,842,600.00. Following the completion of the transaction, the director now directly owns 2,254,015 shares in the company, valued at approximately $276,883,202.60. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO James M. Mock sold 1,321 shares of the business’s stock in a transaction on Wednesday, August 28th. The stock was sold at an average price of $79.39, for a total value of $104,874.19. Following the sale, the chief financial officer now owns 8,600 shares in the company, valued at approximately $682,754. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 78,158 shares of company stock valued at $9,259,012. 15.70% of the stock is currently owned by insiders.

Moderna Stock Down 0.3 %

NASDAQ MRNA opened at $63.94 on Wednesday. The business has a fifty day moving average price of $87.70 and a two-hundred day moving average price of $110.43. The stock has a market capitalization of $24.50 billion, a PE ratio of -4.08 and a beta of 1.67. Moderna, Inc. has a fifty-two week low of $62.55 and a fifty-two week high of $170.47. The company has a debt-to-equity ratio of 0.05, a current ratio of 4.09 and a quick ratio of 3.92.

Moderna (NASDAQ:MRNA) last announced its quarterly earnings data on Thursday, August 1st. The company reported ($3.33) earnings per share for the quarter, topping the consensus estimate of ($3.47) by $0.14. Moderna had a negative return on equity of 21.35% and a negative net margin of 116.18%. The business had revenue of $241.00 million during the quarter, compared to the consensus estimate of $128.41 million. During the same period in the prior year, the company earned ($3.62) EPS. Moderna’s revenue for the quarter was down 29.9% on a year-over-year basis. Equities analysts expect that Moderna, Inc. will post -9.52 earnings per share for the current fiscal year.

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.